Reports Q4 revenue $43.58M, consensus $42.06M. “I am extremely proud of our commercial achievements in 2023,” said Reza Zadno, CEO. “We succeeded in elevating the average monthly utilization in the U.S. by approximately 10%-an exceptional achievement, especially considering the significant 89% increase in our install base. As we enter 2024, we believe there are several positive factors that will enable us to continue to pursue our long-term growth strategy while also demonstrating a disciplined approach on our path to profitability. We believe these underlying fundamentals reflect a technology that is establishing the foundation to become the BPH surgical standard of care and a business poised to be a leading Urology company globally.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
- PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
- Procept BioRobotics price target raised to $58 from $42 at Piper Sandler
- Procept BioRobotics price target raised to $47 from $44 at Wells Fargo
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
